HLA-A*0201–positive Donors Tested
| . | . | Donor . | . | Gag response . | . | Pol Response . | . | HLA-A and HLA-B type . |
|---|---|---|---|---|---|---|---|---|
| Gag Responders | ||||||||
| 1 | 003 | 40 | 3 | A2/3 B7/51 | ||||
| 2 | 031 | 28 | 14 | A1/2 B51/57* | ||||
| 3 | 077 | 22 | 10 | A2/3 B41/49 | ||||
| 4 | 079 | 10 | 3 | A2/32 B7/27 | ||||
| 5 | 102 | 22 | 4 | A2/– B7/57 | ||||
| 6 | 104 | 28 | 4 | A2/11 B7/62 | ||||
| 7 | 324 | 12 | 6 | A2/11 B7/60 | ||||
| 8 | 1M | 50 | 2 | A1/2 B7/57 | ||||
| 9 | 2M | 29 | 3 | A2/6802 B42/51 | ||||
| 10 | 5M | 52 | 2 | A2/32 B7/57 | ||||
| 11 | 22M | 18 | 6 | A2/6802 B41/72 | ||||
| 12 | 25M | 12 | 5 | A2/3 B7/60 | ||||
| 13 | 46M | 23 | 11 | A1/2 B8/62 | ||||
| 14 | 48M | 34 | ND | A2/29 B35/44* | ||||
| 15 | 114 | 23 | 12 | A2/3 B35/–* | ||||
| 16 | 868 | 38 | 23 | A2/24 B27/35 | ||||
| Pol Responders | ||||||||
| 1 | 023 | 3 | 10 | A2/3 B7/51 | ||||
| 2 | 008 | 2 | 21 | A2/6801 B8/65 | ||||
| 3 | 241 | 6 | 30 | A2/26 B39/62 | ||||
| 4 | 065 | 4 | 38 | A1/2 B8/44 | ||||
| 5 | 824 | 0 | 11 | A1/2 B44/57 | ||||
| Equal Gag and Pol/Nonresponders | ||||||||
| 1 | 069 | 21 | 21 | A2/31 B60/62 | ||||
| 2 | 606 | 3 | 1 | A2/− B62/65 | ||||
| 3 | SC7 | 2 | 0 | A1/2 B7/44* | ||||
| . | . | Donor . | . | Gag response . | . | Pol Response . | . | HLA-A and HLA-B type . |
|---|---|---|---|---|---|---|---|---|
| Gag Responders | ||||||||
| 1 | 003 | 40 | 3 | A2/3 B7/51 | ||||
| 2 | 031 | 28 | 14 | A1/2 B51/57* | ||||
| 3 | 077 | 22 | 10 | A2/3 B41/49 | ||||
| 4 | 079 | 10 | 3 | A2/32 B7/27 | ||||
| 5 | 102 | 22 | 4 | A2/– B7/57 | ||||
| 6 | 104 | 28 | 4 | A2/11 B7/62 | ||||
| 7 | 324 | 12 | 6 | A2/11 B7/60 | ||||
| 8 | 1M | 50 | 2 | A1/2 B7/57 | ||||
| 9 | 2M | 29 | 3 | A2/6802 B42/51 | ||||
| 10 | 5M | 52 | 2 | A2/32 B7/57 | ||||
| 11 | 22M | 18 | 6 | A2/6802 B41/72 | ||||
| 12 | 25M | 12 | 5 | A2/3 B7/60 | ||||
| 13 | 46M | 23 | 11 | A1/2 B8/62 | ||||
| 14 | 48M | 34 | ND | A2/29 B35/44* | ||||
| 15 | 114 | 23 | 12 | A2/3 B35/–* | ||||
| 16 | 868 | 38 | 23 | A2/24 B27/35 | ||||
| Pol Responders | ||||||||
| 1 | 023 | 3 | 10 | A2/3 B7/51 | ||||
| 2 | 008 | 2 | 21 | A2/6801 B8/65 | ||||
| 3 | 241 | 6 | 30 | A2/26 B39/62 | ||||
| 4 | 065 | 4 | 38 | A1/2 B8/44 | ||||
| 5 | 824 | 0 | 11 | A1/2 B44/57 | ||||
| Equal Gag and Pol/Nonresponders | ||||||||
| 1 | 069 | 21 | 21 | A2/31 B60/62 | ||||
| 2 | 606 | 3 | 1 | A2/− B62/65 | ||||
| 3 | SC7 | 2 | 0 | A1/2 B7/44* | ||||
HLA class I -A and -B types shown. Gag responders: bulk CTL at E/T 50:1 recognizes the Gag epitope SLYNTVATL, with percent specific lysis >10% (after subtraction of lysis of targets pulsed with no peptide). Specific killing of ILKEPVHGV (Pol) pulsed targets (10 μm) is shown. Pol responders: dominant HLA-A*0201–restricted response is to the Pol epitope. Equal responders: no preference for Gag or Pol epitope. The bulk responses of most of the donors was assayed on several (2–6) occasions; those asterisked were assayed on a single occasion only.